REVIEW

“Red-flag” symptom clusters in transthyretin familial amyloid polyneuropathy

Isabel Conceição1, Alejandra González-Duarte2, Laura Obici3, Hartmut H.-J. Schmidt4, Damien Simoneau5, Moh-Lim Ong6, and Leslie Amass6

1CHLN – Hospital de Santa Maria, and Clinical and Translational Physiology Unit, Faculty of Medicine-IMM, Physiology Institute, Lisbon, Portugal; 2Department of Neurology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, México City, México; 3Amyloidosis Research and Treatment Center, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; 4Klinik für Transplantationsmedizin, Universitätsklinikum Münster, Münster, Germany; 5Medical Division, Pfizer International Operations, Paris, France; and 6Global Medical Affairs, Global Innovative Pharma, Pfizer Inc, New York, NY, USA

Abstract Transthyretin familial amyloid polyneuropathy (TTR-FAP) is a rare, progressive, life-threatening, hereditary disorder caused by mutations in the transthyretin gene and characterized by extracellular deposition of transthyretin-derived amyloid fibrils in peripheral and autonomic nerves, heart, and other organs. TTR-FAP is frequently diagnosed late because the disease is difficult to recognize due to phenotypic heterogeneity. Based on published literature and expert opinion, symptom clusters suggesting TTR-FAP are reviewed, and practical guidance to facilitate earlier diagnosis is provided. TTR-FAP should be suspected if progressive peripheral sensory-motor neuropathy is observed in combination with one or more of the following: family history of a neuropathy, autonomic dysfunction, cardiac hypertrophy, gastrointestinal problems, inexplicable weight loss, carpal tunnel syndrome, renal impairment, or ocular involvement. If TTR-FAP is suspected, transthyretin genotyping, confirmation of amyloid in tissue biopsy, large- and small-fiber assessment by nerve conduction studies and autonomic system evaluations, and cardiac testing should be performed.

Key words: diagnosis, hereditary amyloidosis, transthyretin, transthyretin familial amyloid neuropathy

Introduction Transthyretin familial amyloid polyneuropathy (TTR-FAP) is an autosomal-dominant, adult-onset disorder associated with over 100 different mutations in the transthyretin (TTR) gene that cause transthyretin protein to deposit as amyloid in peripheral and autonomic nerves, heart, gastrointestinal (GI) tract, kidneys, eyes, and connective tissue of the transversal carpal ligament (Ando et al., 2013; Rowczenio et al., 2014; Sekijima, 2015). This results in progressive organ dysfunction and death within an average of 10 years (Ando et al., 2013).

TTR-FAP is a highly heterogeneous disease associated with a wide range of clinical manifestations that may present in varying degrees and combinations (Ando et al., 2013; Sekijima, 2015). It is frequently dominated by progressive and relentless peripheral nerve damage. The disease can be difficult to recognize due to its variable clinical presentation and non-specific symptoms. The age of onset ranges from the second to ninth decade of life (Ando et al., 2013), and incomplete penetrance of clinical disease can lead
to sporadic cases without known affected relatives. Accurate diagnosis of TTR-FAP is often delayed for years (Planté-Bordeneuve et al., 2007; Koike et al., 2011; Dohnn et al., 2013; Adams et al., 2014). Making an accurate diagnosis is important to permit effective disease management, as tissue damage is largely irreversible, and available treatment options are most beneficial in early disease stages (Coelho et al., 2013; Planté-Bordeneuve, 2014; Ericzon et al., 2015). This perspective provides practical guidance on early detection of TTR-FAP.

**Clinical Features of TTR-FAP**

Typical clinical symptoms associated with TTR-FAP are illustrated in Fig. 1. A particular challenge in making a diagnosis is that clinical manifestations are not necessarily uniform among carriers of the same TTR mutation and can vary even within the same family (Ando et al., 2013). The clinical phenotype is also influenced by genetic, epigenetic, or environmental factors other than the TTR mutation (see Table 1). The pattern of amyloid deposition may also play a role (Bergström et al., 2005; Ihse et al., 2013).

Length-dependent peripheral sensory-motor neuropathy is a hallmark feature of TTR-FAP. In classical early-onset (<50 years of age) Val30Met TTR-FAP (Andrade, 1952), distal small myelinated and unmyelinated nerve fibers associated with pain and temperature sensation become damaged first, which may manifest as paresthesia, dysesthesia, allodynia, hyperalgesia, or spontaneous pain in the feet. Axonal degeneration then progresses relentlessly in a distal to proximal pattern reaching upper limbs usually 4 to 5 years after first symptoms. Within a few years, larger myelinated sensory and motor nerve fibers become affected and impairment of light touch, vibration, and position sensation, and motor deficit appear in the distal lower limbs. Motor deficits also follow a length-dependent progression, causing increasing walking difficulty and weakness.

Late-onset cases are characterized by relative preservation of unmyelinated nerve fibers and conspicuous presence of axonal sprouting (Koike et al., 2004). These characteristics are responsible for impaired superficial and deep sensation, severe neuropathic pain, early distal motor involvement, and relatively mild autonomic symptoms (Conceição and De Carvalho, 2007; Koike et al., 2011).

**Common Diagnostic Pitfalls**

The length-dependent pattern of symmetric sensory-motor and autonomic polyneuropathy in TTR-FAP is not unique, and similar neurologic impairments can be observed in many conditions, all of which can mislead clinical diagnosis.

The most common neuropathic misdiagnosis for sporadic TTR-FAP is chronic inflammatory demyelinating polyneuropathy (CIDP) (Planté-Bordeneuve, 2014). For instance, 20% of 90 French patients without a family history of TTR-FAP (Planté-Bordeneuve et al., 2007) and 53% of 15 Japanese patients with sporadic V30M TTR-FAP (Koike et al., 2011) were initially misdiagnosed with CIDP. Although CIDP is generally characterized by a demyelinating sensory-motor neuropathy, once extensive axonal length-dependent damage is present, electrophysiological characteristics of TTR-FAP can resemble those of CIDP due to secondary demyelination. Furthermore, protein levels in cerebrospinal fluid can be elevated in patients with TTR-FAP, albeit less markedly than in CIDP. In some cases, a negative biopsy contributed to misdiagnosis. Given the frequent misdiagnosis, there should be a high suspicion index for TTR-FAP in patients diagnosed with CIDP that do not respond to immunomodulatory treatment.

There have been numerous cases where TTR-related amyloidosis was initially misdiagnosed.
Table 1. Initial symptoms of TTR-FAP.

|                | Portugal n = 483 | Portugal n = 43 | Japan n = 82 | France n = 30 | Mexico n = 58 |
|----------------|------------------|-----------------|--------------|---------------|--------------|
| Val30Met       |                  |                 |              |               |              |
| Early-onset    |                  |                 |              |               |              |
| Late-onset     |                  |                 |              |               |              |
| Early-onset    |                  |                 |              |               |              |
| Late-onset     |                  |                 |              |               |              |
| Val30Met       |                  |                 |              |               |              |
| Non-Val30Met   |                  |                 |              |               |              |
| Ser50Arg,      |                  |                 |              |               |              |
| Ser52Pro, or   |                  |                 |              |               |              |
| Gly47Ala       |                  |                 |              |               |              |
| Age of onset,  |                  |                 |              |               |              |
| years, mean    |                  |                 |              |               |              |
| (SD)           |                  |                 |              |               |              |
| Men            | 31 (3.1)         | 33.1 (5.4)      | 59.5 (6.8)   | 31.9 (7.6)    | 51.3 (15.6)  |
| Women          | 33 (3.3)         | 35%             | 84%          | 57%           | 60%          |
| Sensory-motor  |                  |                 |              |               |              |
| symptoms (%)   | 45.4%            | 35%             | 84%          | 57%           | 60%          |
| Autonomic and  |                  |                 |              |               |              |
| GI symptoms (%)| 65%              | 48%             | 10%          | 35%           | 9%           |
| Impotence      | 5.8%             |                 |              |               |              |

GI, gastrointestinal; TTR-FAP, transthyretin familial amyloid polyneuropathy; SD, standard deviation.

*Less than 50 years of age at symptomatic disease onset.
†At least 50 years of age at symptomatic disease onset.
‡Patients may have more than one first symptom.
§A total of 8.9% of males.
¶Urinary retention might be underdiagnosed as patients are usually not aware or cognisant of symptoms.
Progressive symmetric sensory-motor neuropathy

≥1 of the following

- Family history
- Early autonomic dysfunction (e.g., erectile dysfunction or postural hypotension)
- GI complaints (e.g., chronic diarrhea, constipation, or diarrhea/constipation)
- Unexplained weight loss
- Cardiac hypertrophy, arrhythmias, ventricular blocks, or cardiomyopathy
- Bilateral carpal tunnel syndrome (especially if also present in family members)
- Renal abnormalities (e.g., albuminuria or mild azotemia)
- Vitreous opacities

Additional alert signs:
- Rapid disease progression
- Failure of response to prior therapies

**Figure 2.** Potential “red-flag” symptom clusters that may warn of a diagnosis of transthyretin familial amyloid polyneuropathy (TTR-FAP).

as amyloid light-chain (AL) amyloidosis (Cowan et al., 2011; Briani et al., 2012). Misdiagnosis can be due to occurrence of monoclonal gammopathy in elderly patients or false immunolabeling of amyloid deposits, leading to inappropriate, potentially harmful chemotherapeutic treatment. This can be avoided by careful typing of the amyloid precursor protein.

TTR-FAP is unlikely to be mistaken for other forms of hereditary amyloid neuropathy caused by mutation of the apolipoprotein A-I, gelsolin, or β2-microglobulin genes. However, although very rare and less rapidly progressive, hereditary neuropathy due to truncation mutations of the prion protein can closely mimic TTR-FAP (Mead and Reilly, 2015) and should be considered in the differential diagnosis.

**“Red-flag” Symptom Combinations That May Warn of a Diagnosis of TTR-FAP**

Characteristic features that can help identify TTR-FAP are heritability and general multi-symptom involvement. Consequently, it is important to obtain a complete clinical history with details of symptoms of systemic disease and a complete and detailed family history (Ando et al., 2013; Planté-Bordeneuve, 2014). The occurrence of progressive peripheral sensory-motor polyneuropathy and at least one of the following is suggestive of TTR-FAP: family history of neuropathy, early autonomic dysfunction, cardiac involvement, diarrhea, constipation, alternating episodes of constipation and diarrhea, inexplicable weight loss, carpal tunnel syndrome, renal impairment, or vitreous opacity (Fig. 2).

Of these combinations, peripheral neuropathy with early autonomic signs, such as erectile dysfunction or GI symptoms, and peripheral neuropathy with cardiac manifestations are the most common and important combinations in sporadic patients. Rapid disease progression (Dohrn et al., 2013) and failure to respond to immunomodulatory treatment are additional signs.

**Core Diagnostic Tests to Identify TTR-FAP**

The clusters of clinical symptoms mentioned above should raise suspicion of TTR-FAP, particularly if there is a positive family history. In patients with suspected TTR-FAP, TTR genotyping should be performed. In sporadic cases, the entire coding region of the TTR gene, that is all four exons, should be sequenced. Tissue biopsy analysis and neurologic, cardiac, autonomic, and ophthalmologic evaluation can lend further credence to the correct diagnosis.

**Acknowledgements**

Medical writing support was provided by Susanne Vidot, PhD, of Engage Scientific Solutions and was
funded by Pfizer. Dr. I. C. received support from Alnylam Pharmaceuticals, ISIS Pharmaceuticals, and Pfizer, and serves on the THAOS scientific advisory board. Dr. A. G.-D. received honoraria from Alnylam Pharmaceuticals and Pfizer, and serves on the THAOS scientific advisory board. Dr. L. O. received support from Alnylam Pharmaceuticals to attend scientific meetings and honoraria from Pfizer. Dr. H. H.-J. S. received honoraria from Pfizer. Drs. D. S., M.-L. O., and L. A. are employees of Pfizer.

References

Adams D, Théaudin M, Cauquil C, Algalarrondo V, Slama M (2014). FAP neuropathy and emerging treatments. Curr Neurol Neurosci Rep 14:435.

Ando Y, Coelho T, Berk JL, Cruz MW, Ericzon BG, Ikeda S, Lewis WD, Obici L, Plante-Bordeneuve V, Ravezzi C, Said G, Salvi F (2013). Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J Rare Dis 8:31.

Andrade C (1952). A peculiar form of peripheral neuropathy: familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. Brain 75:408–427.

Bergström J, Gustavsson A, Hellman U, Sletten K, Murphy CL, Weiss DT, Solomon A, Olsson BO, Westermark P (2005). Amyloid deposits in transthyretin-derived amyloidosis: cleaved transthyretin is associated with distinct amyloid morphology. J Pathol 206:224–232.

Briani C, Cavallaro T, Ferrari S, Taitoli F, Calamelli S, Verga L, Adam F, Fabrizi GM (2012). Sporadic transthyretin amyloidosis with a novel TTR gene mutation misdiagnosed as primary amyloidosis. J Neurol 259:2226–2228.

Coelho T, Maia LF, da Silva AM, Cruz MW, Plante-Bordeneuve V, Suhr OB, Conceição I, Schmidt HH, Trigo P, Kelly JW, Labaudiniere R, Chan J, Packman J, Grogan DR (2013). Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol 260:2802–2814.

Conceição I, De Carvalho M (2007). Clinical variability in type I familial amyloid polyneuropathy (Val30Met): comparison between late- and early-onset cases in Portugal. Muscle Nerve 35:116–118.

Coutinho P, da Silva AM, Lima JL, Barbosa AR (1980). Forty years of experience with type I amyloid neuropathy. Review of 483 cases. Amyloid and Amyloidosis. Glenner GG, Costa PP, de Freitas F. Excerpta Medica, Amsterdam, 88–98.

Cowan AJ, Skinner M, Berk JL, Sloan JM, O’Hara C, Seldin DC, Sancorawala V (2011). Macroglossia – not always AL amyloidosis. Amyloid 18:83–86.

Dohrn MF, Röcken C, De Bleeker JL, Martin JJ, Vorgerd M, Van den Bergh PY, Ferbert A, Hinderhofer K, Schröder JM, Weis J, Schulz JB, Claeyss KG (2013). Diagnostic hallmarks and pitfalls in late-onset progressive transthyretin-related amyloid-neuropathy. J Neurol 260:3093–3108.

Ericzon BG, Wilczek HE, Larsson M, Wijayatunga P, Stangou A, Pena JR, Furtado E, Barroso E, Daniel J, Samuel D, Adam R, Karam V, Pauerucha J, Lewis D, Ferraz-Neto BH, Cruz MW, Munar-Ques M, Fabregat J, Ikeda S, Ando Y, Heaton N, Otto G, Suhr O (2015). Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative? Transplantation 99:1847–1854.

González-Duarte A, Lem-Carrillo M, Cardenas-Soto K (2013). Description of transthyretin S50A, S52P and G47A mutations in familial amyloidosis polyneuropathy. Amyloid 20:221–225.

Ihse E, Ravezzi C, Merlino G, Benson MD, Ando Y, Suhr OB, Ikeda S, Lavatelli F, Obici L, Quarta CC, Leone O, Jono H, Ueda M, Lorenzini M, Liepnieks J, Ohshima T, Tasaki M, Yamashita T, Westermark P (2013). Amyloid fibrils containing fragmented ATTR may be the standard fibril composition in ATTR amyloidosis. Amyloid 20:142–150.

Koike H, Misu K, Ikeda S, Ando Y, Nakazato M, Ando E, Yamamoto M, Hattori N, Sobue G (2002). Type I (transthyretin Met30) familial amyloid polyneuropathy in Japan: early- vs late-onset form. Arch Neurol 59:1771–1776.

Koike H, Misu K, Sugiura M, Iijima M, Mori K, Yamamoto M, Hattori N, Mukai E, Ando Y, Ikeda S, Sobue G (2004). Pathology of early- vs late-onset TTR Met30 familial amyloid polyneuropathy. Neurology 63:129–138.

Koike H, Hashimoto R, Tomita M, Kawagashira Y, Iijima M, Tanaka F, Sobue G (2011). Diagnosis of sporadic transthyretin Val30Met familial amyloid polyneuropathy: a practical analysis. Amyloid 18:53–62.

Mead S, Reilly MM (2015). A new prion disease: relationship with central and peripheral amyloidoses. Nat Rev Neurol 11:90–97.

Planté-Bordeneuve V, Lalu T, Misrahi M, Reilly MM, Adams D, Lacroix C, Said G (1998). Genotypic-phenotypic variations in a series of 65 patients with familial amyloid polyneuropathy. Neurology 51:708–714.

Planté-Bordeneuve V, Ferreira A, Lalu T, Zaros C, Lacroix C, Adams D, Said G (2007). Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP). Neurology 69:693–698.

Planté-Bordeneuve V (2014). Update in the diagnosis and management of transthyretin familial amyloid polyneuropathy. J Neurol 261:1227–1233.

Rowczenio DM, Noor I, Gillmore JD, Lachmann HJ, Whelan C, Hawkins PN, Obici L, Westermark P, Grateau G, Wechalekar AD (2014). Online registry for mutations in hereditary amyloidosis including nomenclature recommendations. Hum Mutat 35:E2403–E2412.

Sekijima Y (2015). Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments. J Neurol Neurosurg Psychiatry 86:1036–1043.